Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $33.53 Analyst target: $57.48 Upside: 71.43%
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the Netherlands.
See the full interactive analysis & chart →Informational only — not investment advice.